• TransMedics Group, Inc. reported its fourth-quarter and full-year 2025 results, with revenue rising to US$160.76 million for the quarter and US$605.49 million for the year, alongside higher earnings per share and a net income tax benefit driven by a US$103.3 million U.S. tax valuation allowance release.
• The company also issued 2026 revenue guidance of US$727 million to US$757 million, signaling management’s confidence in continued expansion of its organ care system platform and related services.
• We’ll now explore how the robust 2025 earnings and 2026 revenue outlook could influence TransMedics’ investment narrative and future expectations.

AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

TransMedics Group Investment Narrative Recap

To own TransMedics, you need to believe its organ care technology and integrated transplant services can remain the preferred option for centers and payers. The strong 2025 results and new 2026 revenue guidance reinforce that story, but they also sharpen the key near term catalyst and risk: sustaining clinical and commercial traction for the organ care platform while higher R&D and infrastructure spending, along with closer regulatory scrutiny, could weigh on margins and operating flexibility.

The most relevant announcement here is the 2026 revenue outlook of US$727 million to US$757 million, issued alongside the 2025 results. This guidance frames how management currently sees demand for the organ care system and related services and sits against earlier concerns about international expansion, competitive pressure, and capital intensity. How well actual 2026 performance tracks this range will be an important reference point for investors weighing both the upside and these ongoing risks.

Yet beneath the headline growth, investors should be aware that rising investment needs and evolving regulatory expectations could...

TransMedics Group's narrative projects $890.5 million revenue and $155.9 million earnings by 2028.

Uncover how TransMedics Group's forecasts yield a $144.20 fair value, in line with its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were assuming revenue could reach about US$963 million and earnings US$189 million by 2028, which is far more upbeat than consensus. If you lean toward that view, the latest results and guidance might reinforce it, but they could also shift how you weigh the risk that expanding R&D and infrastructure spending fails to translate into the kind of margin gains those forecasts implied.

Explore 10 other fair value estimates on TransMedics Group - why the stock might be worth as much as 64% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your TransMedics Group research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free TransMedics Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TransMedics Group's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.